Clinical Trial Update: 177LuPSMA in Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Lutetium-177 labeled PSMA radioligand (177Lu-PSMA) in advanced renal cell carcinoma. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• 177Lu-PSMA

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING